In China, nab-paclitaxel has not been used for a long time, and the effectiveness and safety of nab-paclitaxel combined with anti-HER2 agents for treating HER2-positive breast cancer patients need further clinical observation. This evidence concerns the gene ERBB2 and breast carcinoma.